Mouse Recombinant CFI protein, His Tag (V2LY-0526-LY8290)

Name: Mouse Recombinant CFI protein, His Tag
SKU: V2LY-0526-LY8290
Rating: 5 (1 reviews)

See all CFI antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

HEK293 Cells

Protein Species

Mouse

Tag

His Tag

Protein Construction

This product is Mouse Recombinant CFI protein, His Tag consist of Amino Acid: 1-603 and predicts a molecular mass of 66.75 kDa.

Molecule Mass

66.75 kDa

Verified

HPLC

Sequence

Amino Acid: 1-603

Species

Mouse

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

≥95% as determined by SDS-PAGE. ≥90% as determined by SEC-HPLC.

Endotoxin

Please contact us for more information.

Format

Lyophilized

Reconstitution

Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.

Buffer

Lyophilized from sterile Tirs, NaCl, Glycerol

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

Complement Factor I

Function

Trypsin-like serine protease that plays an essential role in regulating the immune response by controlling all complement pathways. Inhibits these pathways by cleaving three peptide bonds in the alpha-chain of C3b and two bonds in the alpha-chain of C4b thereby inactivating these proteins (PubMed:7360115, PubMed:17320177).
Essential cofactors for these reactions include factor H and C4BP in the fluid phase and membrane cofactor protein/CD46 and CR1 on cell surfaces (PubMed:2141838, PubMed:9605165, PubMed:12055245).
The presence of these cofactors on healthy cells allows degradation of deposited C3b by CFI in order to prevent undesired complement activation, while in apoptotic cells or microbes, the absence of such cofactors leads to C3b-mediated complement activation and subsequent opsonization (PubMed:28671664).

Biological Process

Complement activation, classical pathway Source: UniProtKB-KW
Innate immune response Source: UniProtKB-KW
Regulation of complement activation Source: Reactome
Viral process Source: UniProtKB-KW

Cellular Location

Extracellular space; Secreted

Involvement in disease

Hemolytic uremic syndrome atypical 3 (AHUS3): An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease.
Complement factor I deficiency (CFI deficiency): Autosomal recessive condition associated with a propensity to pyogenic infections.
Macular degeneration, age-related, 13 (ARMD13): A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

Jia, B. B., Jin, C. D., & Li, M. F. (2020). The trypsin-like serine protease domain of Paralichthys olivaceus complement factor I regulates complement activation and inhibits bacterial growth. Fish & shellfish immunology, 97, 18-26.

Hallam, T. M., Marchbank, K. J., Harris, C. L., Osmond, C., Shuttleworth, V. G., Griffiths, H., ... & Lotery, A. J. (2020). Rare genetic variants in complement factor I lead to low FI plasma levels resulting in increased risk of age-related macular degeneration. Investigative ophthalmology & visual science, 61(6), 18-18.

Lv, W., Ma, A., Chi, X., Li, Q., Pang, Y., & Su, P. (2020). A novel complement factor I involving in the complement system immune response from Lampetra morii. Fish & shellfish immunology, 98, 988-994.

Altmann, T., Torvell, M., Owens, S., Mitra, D., Sheerin, N. S., Morgan, B. P., ... & Forsyth, R. (2020). Complement factor I deficiency: A potentially treatable cause of fulminant cerebral inflammation. Neurology-Neuroimmunology Neuroinflammation, 7(3).

Yu, Q., Zhu, J., Yao, Y., & Sun, C. (2020). Complement family member CFI polymorphisms and AMD susceptibility from a comprehensive analysis. Bioscience reports, 40(4), BSR20200406.

Shields, A. M., Pagnamenta, A. T., Pollard, A. J., Taylor, J. C., Allroggen, H., Patel, S. Y., ... & Smith, C. (2019). Classical and non-classical presentations of complement factor I deficiency: two contrasting cases diagnosed via genetic and genomic methods. Frontiers in immunology, 10, 1150.

Tseng, M. H., Lin, S. H., Wu, C. Y., Chien, H. P., Yang, H. Y., Chen, Y. C., ... & Huang, J. L. (2018). Serum complement factor I is associated with disease activity of systemic lupus erythematosus. Oncotarget, 9(9), 8502.

Lashkari, K., Teague, G., Chen, H., Lin, Y. Q., Kumar, S., McLaughlin, M. M., & López, F. J. (2018). A monoclonal antibody targeting amyloid β (Aβ) restores complement factor I bioactivity: Potential implications in age-related macular degeneration and Alzheimer’s disease. PLoS One, 13(5), e0195751.

Nanthapisal, S., Eleftheriou, D., Gilmour, K., Leone, V., Ramnath, R., Omoyinmi, E., ... & Brogan, P. A. (2018). Cutaneous vasculitis and recurrent infection caused by deficiency in complement factor I. Frontiers in immunology, 9, 735.

Franco-Jarava, C., de la Campa, E. Á., Solanich, X., Morandeira-Rego, F., Mas-Bosch, V., García-Prat, M., ... & Colobran, R. (2017). Early versus late diagnosis of complement factor I deficiency: clinical consequences illustrated in two families with novel homozygous CFI mutations. Journal of clinical immunology, 37(8), 781-789.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Recombinant CFI protein, His Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Human CFI ELISA Kit (CAT#: V2LY-0626-LY3846)

Related Products

Mouse Anti-CFI Recombinant Antibody (CBFYC-1766) (CAT#: CBMAB-C1828-FY)

Mouse Anti-CFI Recombinant Antibody (CBFYC-1765) (CAT#: CBMAB-C1827-FY)

Mouse Anti-CFI Recombinant Antibody (CBFYC-1764) (CAT#: CBMAB-C1826-FY)

Rabbit Anti-CFI Recombinant Antibody (CBFYC-1767) (CAT#: CBMAB-C1829-FY)

Mouse Anti-CFI Recombinant Antibody (KT22) (CAT#: CBMAB-F0689-CQ)

Human CFI ELISA Kit (CAT#: V2LY-0626-LY3846)

Mouse Anti-CFI Recombinant Antibody (11G3) (CAT#: CBMAB-C2523-LY)

Mouse Anti-CFI Recombinant Antibody (CBXF-2129) (CAT#: CBMAB-F1367-CQ)

Mouse Anti-CFI Recombinant Antibody (1B3) (CAT#: CBMAB-C3639-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry